United Therapeutics Corp. (UTHR): Today's Most Compelling Stock Buy

A generic image of a pen a chart Credit: Shutterstock photo

SoTM Bull's Eye Report - Today's Most Compelling Buy

Monday, April 22, 2013

At StateoftheMarkets.com, we strive to "own the best and ignore the rest" in our equity portfolios. Toward this end, each day we search our database for a "top stock" (a top rated company in terms of earnings strength as well as company and industry performance) that presents a strong technical "set up" and a good entry point.

In short, when our equity team is looking to add a stock to one of our portfolios, the "bull's eye" stock shown below is generally their first choice.







% Gain S.T.


Loss United Therapeutics Corp UTHR Biotechnology 9.8 +11.95% .02

Why We Like The Stock:

United Therapeutics Corp (UTHR) is our most compelling buy today due to the fact that it is a top- rated stock (in terms of earnings strength and company/industry performance) in the top- rated industry, Biotechnology. Biotech stocks have been absolutely on fire this month, and the sub-industry is rated the highest in our momentum rankings. While Health Care in general (XLV) is outperforming, it only takes a quick glance at the SPDR Biotechnology ETF (XBI) to see where the upward thrust is coming from. UTHR has been having a great year so far, and has been trending higher since late October 2012. The last time the stock closed below its 50-day moving average was in early December, which is a great sign. In early April and again last week, UTHR held support around .50, and looks like it has turned a corner. Currently, the stock is crossing above its short-term moving averages and looks poised for a run back up to recent mid-March highs just north of . We like this reasonably priced Biotech company here as long as it holds above its April 5 low of .02.We Would Be Buyers:

At the current price (~.00), or on a pullback to the 50-day moving average (.69).

Looking to trade the Bull's Eye stock picks? Click here to download our free Special Report, "How We Identify Our “Bull’s Eye” Picks & How You Can Profit Trading Them"Company Profile:

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. The Company’s therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor, Monoclonal Antibodies (MAbs), Glycobiology Antiviral Agents and Cell-Based Therapy. Its product portfolio includes Remodulin, Tyvaso, Adcirca, Oral Treprostinil (UT-15C), Oral Treprostinil (UT-15C) Combination Therapy, Ch14.18 MAb, Beraprost-MR, 8H9 MAb, IW001, Glycobiology Antiviral Agents, PLX Cells, and Pulmonary Tissue Replacement and Remodeling. On July 11, 2011, the Company acquired 100% interest in Revivicor, Inc. (Revivicor). On March 31, 2011, the Company sold 100% interest in Medicomp, Inc. (Medicomp). In June 2011, it discontinued its telemedicine-related activities.

Stock Rating:

The Stock Rating indicates the combined score of our proprietary Earning Strength and Company Performance models. The rating scale is 0 - 10 with 10 being the highest.


At the time of publication the editor and affiliated companies own the following positions: UTHR

Note: Positions may be bought or sold while this publication is in circulation without notice.

United Therapeutics Corp - Last 3 Months

United Therapeutics Corp - Last 12 Months

United Therapeutics Corp - Last 5 Years

The analysis and information in this report and on our website is for informational purposes only. No part of the material presented in this report or on our websites is intended as an investment recommendation or investment advice. Neither the information nor any opinion expressed nor any Portfolio constitutes a solicitation to purchase or sell securities or any investment program. The opinions and forecasts expressed are those of the editors of StateoftheMarkets.com and may not actually come to pass. The opinions and viewpoints regarding the future of the markets should not be construed as recommendations of any specific security nor specific investment advice. Stocks should always consult an investment professional before making any investment.

Any investment decisions must in all cases be made by the reader or by his or her investment adviser. Do NOT ever purchase any security without doing sufficient research. There is no guarantee that the investment objectives outlined will actually come to pass. All opinions expressed herein are subject to change without notice. Neither the editor, employees, nor any of their affiliates shall have any liability for any loss sustained by anyone who has relied on the information provided.

The analysis provided is based on both technical and fundamental research and is provided 'as is' without warranty of any kind, either expressed or implied. Although the information contained is derived from sources which are believed to be reliable, they cannot be guaranteed.

The information contained in our websites and StateoftheMarkets.com publications is provided by Ridge Publishing Co. Inc. (Ridge). One of the principals of Ridge, Mr. David Moenning, is also President and majority shareholder of Heritage Capital Management, Inc. (HCM) a Chicago-based money management firm. HCM is registered as an investment adviser. HCM also serves as a sub-advisor to other investment advisory firms. Ridge is a publisher and has not registered as an investment adviser. Neither HCM nor Ridge is registered as a broker-dealer.

Employees and affiliates of HCM and Ridge may at times have positions in the securities referred to and may make purchases or sales of these securities while publications are in circulation. Editors will indicate whether they or HCM has a position in stocks or other securities mentioned in any publication. The disclosures will be accurate as of the time of publication and may change thereafter without notice.

Index returns are price only and do not include the reinvestment of dividends. The S&P 500 is a stock market index containing the stocks of 500 large-cap corporations, most of which are US companies. The index is the most notable of the many indices owned and maintained by Standard & Poor's, a division of McGraw-Hill. S&P 500 is used in reference not only to the index but also to the 500 companies that have their common stock included in the index.

Investments in equities carry an inherent element of risk including the potential for significant loss of principal. Past performance is not an indication of future results.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.